Sera Prognostics (SERA) Long-Term Debt Repayments (2020 - 2021)

Sera Prognostics (SERA) posted Long-Term Debt Repayments of $4.5 million for Q1 2021, up 349.4% on a QoQ basis from $1.0 million in Q4 2020.

Sera Prognostics (SERA) Long-Term Debt Repayments (2020 - 2021) Analysis & Trends

Sera Prognostics' Long-Term Debt Repayments history runs 2 years deep, the most recent figure standing at $4.5 million for Q1 2021.

Quarterly Long-Term Debt Repayments changed N/A year-over-year to $4.5 million in Q1 2021, while the trailing twelve-month figure through Dec 2021 was $4.5 million (changed N/A YoY) and the FY2021 annual result came in at $4.5 million, up 68.5% from the prior year.
Long-Term Debt Repayments was $4.5 million for Q1 2021 at Sera Prognostics, up from $1.0 million in the prior quarter.
Across five years, Long-Term Debt Repayments topped out at $4.5 million in Q1 2021 and bottomed at $1.0 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Abbott Laboratories	183.47 Bn	176.17 Bn	6.27 Bn	1.42 Bn
2	Stryker	128.89 Bn	126.01 Bn	3.81 Bn	1.00 Bn
3	Medtronic	108.71 Bn	99.49 Bn	6.41 Bn	-
4	Boston Scientific	68.50 Bn	67.05 Bn	3.61 Bn	-
5	Edwards Lifesciences	48.59 Bn	44.92 Bn	1.29 Bn	-
6	Dexcom	28.40 Bn	27.29 Bn	750.30 Mn	-
7	GE HealthCare Technologies	28.34 Bn	26.06 Bn	1.98 Bn	-
8	Smith & Nephew	26.93 Bn	26.35 Bn	-	-
9	Koninklijke Philips	25.50 Bn	22.37 Bn	2.07 Bn	-64.39 Mn
10	Sera Prognostics	107.05 Mn	107.05 Mn	-28,000.00	-

Download Data